< Back to previous page

Publication

Ocrelizumab phase iiib efficacy from casting: 2-year neda (mri re-baselined) subgroup rates in rrms patients with a suboptimal response to prior dmts

Journal Contribution - Journal Abstract Conference Contribution

Journal: Multiple Sclerosis Journal

ISSN: 1352-4585

Issue: 3_SUPPL

Volume: 26

Pages: 224 - 225

Publication year:2020

WoS Id: 000596547100445
Handle: http://hdl.handle.net/1942/33149

Accessibility:Closed